The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Kelly Timothy P | Chief Technology Officer | Sell(S) | 6K | $1.93 | $12K |
| Feb 24, 2026 | McClung Barbara G | Chief Legal Officer | Sell(S) | 7K | $1.96 | $14K |
| Feb 24, 2026 | Kelly Timothy P | Chief Technology Officer | Sell(S) | 3K | $1.96 | $6K |
| Feb 24, 2026 | Khan Ruhi Ahmad | Chief Business Officer | Sell(S) | 7K | $1.96 | $14K |
| Feb 24, 2026 | Albertson Tina M. | Chief Medical Officer | Sell(S) | 1K | $1.96 | $2K |
| Feb 20, 2026 | Guggenhime Andrew | Director | Grant(A) | 45K | — | $0 |
| Feb 20, 2026 | McClung Barbara G | Chief Legal Officer | Grant(A) | 45K | — | $0 |
| Feb 20, 2026 | McClung Barbara G | Chief Legal Officer | Grant(A) | 203K | — | $0 |
| Feb 20, 2026 | Braunstein Scott | Director | Grant(A) | 45K | — | $0 |
| Feb 20, 2026 | Haurwitz Rachel E. | President and CEO, Director | Grant(A) | 152K | — | $0 |
| Feb 20, 2026 | Haurwitz Rachel E. | President and CEO, Director | Grant(A) | 683K | — | $0 |
| Feb 20, 2026 | Sacks Natalie | Director | Grant(A) | 45K | — | $0 |
| Feb 20, 2026 | Johnson David Lee | Director | Grant(A) | 45K | — | $0 |
| Feb 20, 2026 | Kelly Timothy P | Chief Technology Officer | Grant(A) | 45K | — | $0 |
| Feb 20, 2026 | Kelly Timothy P | Chief Technology Officer | Grant(A) | 203K | — | $0 |
| Feb 20, 2026 | Ryali Sriram | Chief Financial Officer | Grant(A) | 55K | — | $0 |
| Feb 20, 2026 | Ryali Sriram | Chief Financial Officer | Grant(A) | 248K | — | $0 |
| Feb 20, 2026 | Whiting Nancy | Director | Grant(A) | 45K | — | $0 |
| Feb 20, 2026 | Zheng Ran | Director | Grant(A) | 45K | — | $0 |
| Feb 20, 2026 | Khan Ruhi Ahmad | Chief Business Officer | Grant(A) | 45K | — | $0 |
| Feb 20, 2026 | Khan Ruhi Ahmad | Chief Business Officer | Grant(A) | 203K | — | $0 |
| Feb 20, 2026 | Richardson-Heron Dara | Director | Grant(A) | 45K | — | $0 |
| Feb 20, 2026 | Albertson Tina M. | Chief Medical Officer | Grant(A) | 55K | — | $0 |
| Feb 20, 2026 | Albertson Tina M. | Chief Medical Officer | Grant(A) | 248K | — | $0 |
| Mar 14, 2025 | Haurwitz Rachel E. | President and CEO, Director | Buy(P) | 20K | $1.02 | $20K |
| Feb 21, 2025 | McClung Barbara G | Chief Legal Officer | Sell(S) | 4K | $1.35 | $5K |
| Feb 21, 2025 | Kanner Steven | Chief Scientific Officer | Sell(S) | 4K | $1.35 | $5K |
| Feb 21, 2025 | Khan Ruhi Ahmad | Chief Business Officer | Sell(S) | 4K | $1.35 | $5K |
| Feb 20, 2025 | Guggenhime Andrew | Director | Grant(A) | 41K | — | $0 |
| Feb 20, 2025 | McClung Barbara G | Chief Legal Officer | Grant(A) | 38K | — | $0 |
| Feb 20, 2025 | McClung Barbara G | Chief Legal Officer | Grant(A) | 170K | — | $0 |
| Feb 20, 2025 | Braunstein Scott | Director | Grant(A) | 41K | — | $0 |
| Feb 20, 2025 | Haurwitz Rachel E. | President and CEO, Director | Grant(A) | 137K | — | $0 |
| Feb 20, 2025 | Haurwitz Rachel E. | President and CEO, Director | Grant(A) | 618K | — | $0 |
| Feb 20, 2025 | Sacks Natalie | Director | Grant(A) | 41K | — | $0 |
| Feb 20, 2025 | Johnson David Lee | Director | Grant(A) | 41K | — | $0 |
| Feb 20, 2025 | Kelly Timothy P | Chief Technology Officer | Grant(A) | 38K | — | $0 |
| Feb 20, 2025 | Kelly Timothy P | Chief Technology Officer | Grant(A) | 170K | — | $0 |
| Feb 20, 2025 | Kanner Steven | Chief Scientific Officer | Grant(A) | 38K | — | $0 |
| Feb 20, 2025 | Kanner Steven | Chief Scientific Officer | Grant(A) | 170K | — | $0 |
| Feb 20, 2025 | Whiting Nancy | Director | Grant(A) | 41K | — | $0 |
| Feb 20, 2025 | Zheng Ran | Director | Grant(A) | 41K | — | $0 |
| Feb 20, 2025 | Khan Ruhi Ahmad | Chief Business Officer | Grant(A) | 38K | — | $0 |
| Feb 20, 2025 | Khan Ruhi Ahmad | Chief Business Officer | Grant(A) | 170K | — | $0 |
| Feb 20, 2025 | Richardson-Heron Dara | Director | Grant(A) | 41K | — | $0 |
| Feb 20, 2025 | Albertson Tina M. | Chief Medical Officer | Grant(A) | 15K | — | $0 |
| Feb 20, 2025 | Albertson Tina M. | Chief Medical Officer | Grant(A) | 66K | — | $0 |
| Jan 29, 2025 | Ryali Sriram | Chief Financial Officer | Buy(P) | 17K | $1.42 | $25K |
| Jan 10, 2025 | Ryali Sriram | Chief Financial Officer | Grant(A) | 300K | — | $0 |
| Nov 20, 2024 | Fischesser Ryan | VP of Finance and Controller | Grant(A) | 25K | — | $0 |
| Aug 19, 2024 | Albertson Tina M. | Chief Medical Officer | Grant(A) | 300K | — | $0 |
| Feb 20, 2024 | Braunstein Scott | Director | Grant(A) | 40K | — | $0 |
| Feb 20, 2024 | Guggenhime Andrew | Director | Grant(A) | 40K | — | $0 |
| Feb 20, 2024 | Johnson David Lee | Director | Grant(A) | 40K | — | $0 |
| Feb 20, 2024 | Richardson-Heron Dara | Director | Grant(A) | 40K | — | $0 |
| Feb 20, 2024 | Sacks Natalie | Director | Grant(A) | 40K | — | $0 |
| Feb 20, 2024 | Whiting Nancy | Director | Grant(A) | 40K | — | $0 |
| Feb 20, 2024 | Zheng Ran | Director | Grant(A) | 40K | — | $0 |
| Feb 20, 2024 | Kanner Steven | Chief Scientific Officer | Grant(A) | 33K | — | $0 |
| Feb 20, 2024 | Kanner Steven | Chief Scientific Officer | Grant(A) | 153K | — | $0 |
| Feb 20, 2024 | Haurwitz Rachel E. | President and CEO, Director | Grant(A) | 119K | — | $0 |
| Feb 20, 2024 | Haurwitz Rachel E. | President and CEO, Director | Grant(A) | 547K | — | $0 |
| Feb 20, 2024 | Khan Ruhi Ahmad | Chief Business Officer | Grant(A) | 33K | — | $0 |
| Feb 20, 2024 | Khan Ruhi Ahmad | Chief Business Officer | Grant(A) | 153K | — | $0 |
| Feb 20, 2024 | McClung Barbara G | Chief Legal Officer | Grant(A) | 33K | — | $0 |
| Feb 20, 2024 | McClung Barbara G | Chief Legal Officer | Grant(A) | 153K | — | $0 |
| Feb 20, 2024 | O'Byrne Jason | Chief Financial Officer | Grant(A) | 33K | — | $0 |
| Feb 20, 2024 | O'Byrne Jason | Chief Financial Officer | Grant(A) | 153K | — | $0 |
| Feb 6, 2024 | Kanner Steven | Chief Scientific Officer | Option exercise(M) | 31K | $2.69 | $82K |
| Feb 6, 2024 | Kanner Steven | Chief Scientific Officer | Option exercise(M) | 31K | — | $0 |
| Jan 8, 2024 | Kelly Timothy P | Chief Technology Officer | Grant(A) | 300K | — | $0 |
| Jun 8, 2023 | Haurwitz Rachel E. | President and CEO, Director | Option exercise(M) | 10K | $2.96 | $30K |
| Jun 8, 2023 | Haurwitz Rachel E. | President and CEO, Director | Option exercise(M) | 10K | — | $0 |
| Mar 20, 2023 | Haurwitz Rachel E. | President and CEO, Director | Option exercise(M) | 10K | $2.96 | $30K |
| Mar 20, 2023 | Haurwitz Rachel E. | President and CEO, Director | Option exercise(M) | 10K | — | $0 |
| Feb 21, 2023 | Johnson David Lee | Director | Grant(A) | 22K | — | $0 |
| Feb 21, 2023 | O'Byrne Jason | Chief Financial Officer | Grant(A) | 131K | — | $0 |
| Feb 21, 2023 | Whiting Nancy | Director | Grant(A) | 22K | — | $0 |
| Feb 21, 2023 | Zheng Ran | Director | Grant(A) | 22K | — | $0 |
| Feb 21, 2023 | Rizvi Syed Ali-aamir | Chief Medical Officer | Grant(A) | 131K | — | $0 |
| Feb 21, 2023 | McClung Barbara G | Chief Legal Officer | Grant(A) | 131K | — | $0 |
| Feb 21, 2023 | Guggenhime Andrew | Director | Grant(A) | 22K | — | $0 |
| Feb 21, 2023 | Braunstein Scott | Director | Grant(A) | 22K | — | $0 |
| Feb 21, 2023 | Sacks Natalie | Director | Grant(A) | 22K | — | $0 |
| Feb 21, 2023 | Khan Ruhi Ahmad | Chief Business Officer | Grant(A) | 131K | — | $0 |
| Feb 21, 2023 | Richardson-Heron Dara | Director | Grant(A) | 22K | — | $0 |
| Feb 21, 2023 | Kanner Steven | Chief Scientific Officer | Grant(A) | 131K | — | $0 |
| Feb 21, 2023 | Haurwitz Rachel E. | President and CEO, Director | Grant(A) | 511K | — | $0 |
| Jan 19, 2023 | Rizvi Syed Ali-aamir | Chief Medical Officer | Sell(S) | 6K | $6.31 | $36K |
| Dec 2, 2022 | Kanner Steven | Chief Scientific Officer | Option exercise(M) | 21K | $2.69 | $58K |
| Dec 2, 2022 | Kanner Steven | Chief Scientific Officer | Option exercise(M) | 21K | $2.69 | $58K |
| Oct 6, 2022 | Fischesser Ryan | VP of Finance and Controller | Option exercise(M) | 3K | $2.69 | $8K |
| Oct 6, 2022 | Fischesser Ryan | VP of Finance and Controller | Option exercise(M) | 3K | $4.11 | $12K |
| Oct 6, 2022 | Fischesser Ryan | VP of Finance and Controller | Sell(S) | 10K | $10.80 | $108K |
| Oct 6, 2022 | Fischesser Ryan | VP of Finance and Controller | Option exercise(M) | 3K | — | $0 |
| Oct 6, 2022 | Fischesser Ryan | VP of Finance and Controller | Option exercise(M) | 3K | — | $0 |
| Sep 15, 2022 | McClung Barbara G | Chief Legal Officer | Option exercise(M) | 77 | $2.69 | $207 |
| Sep 15, 2022 | McClung Barbara G | Chief Legal Officer | Option exercise(M) | 28K | $2.69 | $74K |
| Sep 15, 2022 | McClung Barbara G | Chief Legal Officer | Option exercise(M) | 77 | — | $0 |
| Sep 15, 2022 | McClung Barbara G | Chief Legal Officer | Option exercise(M) | 28K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).